Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …

Background In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab
and capecitabine significantly improved overall survival (OS) and progression-free survival …

Simple Summary The development of drug resistance in HER2 targeted therapies poses a
major challenge in breast cancer treatment. To address this challenge, researchers have …

Simple Summary Leptomeningeal metastases represent an unmet need due to the lack of
effective therapy and poor survival. The tyrosine kinase inhibitor, neratinib, has …

Breast cancer brain metastases (BM) are associated with a dismal prognosis and very
limited treatment options. Standard chemotherapy is challenging in BM patients because the …

Background Little is known about the association between air pollution and self-perceived
health (including both health-related quality of life [HRQoL] and self-rated health [SRH]). The …

Human epidermal growth factor receptor 2-tyrosine kinase inhibitors (HER2-TKIs) have
been extensively utilized for treating HER2-positive metastatic breast cancer (MBC), with …

“A man's got to know his limitations.” So goes Clint Eastwood's unforgettable line in his role
as inspector “Dirty Harry,” from the 1973 movie Magnum Force. Limitation was the theme in …

Simple Summary Treatment options for patients with Human Epidermal growth factor
Receptor 2 positive (HER2+) metastatic breast cancer are rapidly changing, especially for …

In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2
positive breast cancer were published. To bring this new evidence into a clinical …